SCIENCE & INNOVATION
Addresses scientific advances, emerging cell and cell-based therapeutic platforms, as well as technological developments
in pre-clinical CGT research with clinical implications.
TRANSLATION TO CLINIC
This segment addresses topics arising in moving from pre-clinical research to First in Human studies, including results from promising Phase I clinical trials, process development, clinical trial development with an eye to eventual market-authorization and product launch, early-stage CMC, regulatory requirements, and sustainable business models.
FROM FIRST IN HUMAN TO CLINICAL ACCELERATION
Addresses topics arising in moving from Phase I of clinical trials through to marketing authorization, including results of promising Phase II/III clinical trials, discussions of regulatory requirements and barriers to approval, COGs, business models and operational structures to scale up, partnering and investment.
LAUNCH & PATIENT ACCESS
Addresses topics arising in bringing about the clinical adoption of market-authorized CGT products for patients globally, for example, discussions on pricing and reimbursement, business models, scaling up and scaling out, global launch strategies, and real-world evidence.